CHA Biotech
Financials
Valuation Metrics
CHA Biotech's Market Cap is ₩6322B. At end of 2025 it was ₩1.4T. Ranked #376 of 2,405 in KR market (top 16%), #123 of 1,627 on KOSDAQ (top 8%), #9 of 94 in Health Care Equipment & Services (top 10%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 632.22B KRW | KR#376/2,405 Sec#9/94 |
| Revenue | 1.31T KRW | KR#346/2,405 Sec#2/94 |
| Net Income | -16.43B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 2.86T KRW | KR#248/2,405 Sec#2/94 |
| Net Assets | 1.03T KRW | KR#290/2,405 Sec#3/94 |
| Employees | 334 | KR#719/2,405 Sec#19/94 |
| Value | ||
| P/B | 0.62x | KR#1,078/2,405 Sec#20/94 |
| P/S | 0.48x | KR#945/2,405 Sec#9/94 |
| FCF Yield | -34.72% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -1.60% | KR#1,658/2,405 Sec#56/94 |
| ROA | -0.57% | KR#1,623/2,405 Sec#53/94 |
| Op. Margin | -5.68% | KR#1,870/2,405 Sec#59/94 |
| Revenue Growth | 13.93% | KR#718/2,405 Sec#38/94 |
| Financial Health | ||
| Debt Ratio | 178.44% | KR#2,020/2,405 Sec#87/94 |
| Total Debt | 1.29T KRW | KR#174/2,405 Sec#1/94 |
| FCF | -219.51B KRW | KR#2,164/2,405 Sec#84/94 |
| Cash | 303.36B KRW | KR#193/2,405 Sec#1/94 |
| Current Ratio | 0.89x | KR#1,842/2,405 Sec#83/94 |
| Dividend | ||
| Div. Yield | 0.13% | KR#1,362/2,405 Sec#39/94 |
| Div. Growth | -67.82% | KR—/2,405 Sec—/94 |
| Performance | ||
| 1Y Return | -44.67% | KR#1,908/2,405 Sec#67/94 |
| 1M Return | -19.62% | KR#1,854/2,405 Sec#78/94 |
| From 52W High | -71.61% | KR#2,103/2,405 Sec#80/94 |
| 1Y MDD | -71.70% | KR#2,027/2,405 Sec#75/94 |
| Trading | ||
| Volume | 111,566 shares | KR#589/2,405 Sec#22/94 |
| Trading Value | 751.8M KRW | KR#666/2,405 Sec#17/94 |
| Foreign Own. | 7.88% | KR#563/2,405 Sec#16/94 |
| Per Share | ||
| EPS | -177 KRW | KR—/2,405 Sec—/94 |
| BPS | 11,044 KRW | KR#928/2,405 Sec#18/94 |
Company Info
CHA Biotech, established in 2002, engages in umbilical cord blood banking, stem cell research and cell therapy development, and anti-aging services. Through its major subsidiaries, the company operates pharmaceutical, global CDMO, and global medical network businesses, leveraging an ecosystem-based clinical and new drug development platform. Revenue generation is expected from advanced regenerative medicine treatment sales and global out-licensing. It is also strengthening its global network by establishing the world's largest Cell and Gene Therapy (CGT) manufacturing facility. CHA Biotech is headquartered in Gangnam-gu, Seoul.